Aclarion Implements Reverse Stock Split to Meet Nasdaq Listing Requirements

Aclarion, Inc., a healthcare technology company specializing in chronic low back pain diagnostic technologies, will implement a reverse stock split to improve its stock market position and comply with Nasdaq listing requirements.

The company's stockholders previously approved an amendment to its Certificate of Incorporation allowing for a reverse stock split, with the Board of Directors setting the ratio at 1-for-335. This means every 335 existing shares will be consolidated into a single share of common stock.

The primary motivation behind this strategic financial maneuver is to increase the per-share stock price and meet Nasdaq's Minimum Bid Price Rule, which requires shares to trade above $1.00. By reducing the number of outstanding shares from approximately 169.4 million to around 500,000, Aclarion aims to enhance its market attractiveness and maintain its Nasdaq listing.

The reverse stock split will be effective before market open on January 30, 2025, with shares assigned a new CUSIP number. Stockholders with brokerage accounts will see automatic adjustments, while those holding physical stock certificates will receive transmission instructions from Vstock Transfer.

Importantly, the split will proportionally impact all outstanding warrants, stock options, and restricted stock units, ensuring no fundamental change in the underlying value of these securities. No fractional shares will be issued, with smaller shareholdings rounded up to a whole share.

This financial restructuring reflects Aclarion's commitment to maintaining its position in the healthcare technology sector and its Nociscan platform, which uses magnetic resonance spectroscopy to help physicians identify chronic low back pain sources.